| 摘要 |
Compounds of formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis wherein: Y is CR'R' or NR'C(O); R<1> is -C0-6alkyl-Het-, -C0-6alkyl-Ar, H, -C1-6alkyl, -CN or -S(O)kR<g>; R<2> is (a), (b), (c), (d) or (e); W is -(CHR<g>)a-U-(CHR<g>)b-; U is absent or CO, CR<g>2, C(=CR<g>2), S(O)k, O, NR<g>, CR<g>OR<g>, CR<g>(OR<k>)CR<g>2, CR<g>2CR<g>(OR<k>), C(O)CR<g>2, CR<g>2C(O), CONR<i>, NR<i>CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR<g>, NR<g>C(S), S(O)2NR<g>, NR<g>S(O)2 N=N, NR<g>NR<g>, NR<g>CR<g>2, CR<g>2NR<g>, CR<g>2O, OCR<g>2, CC , CR<g>=CR<g>, Ar or Het; G is NR<e>, S or O; R<g> is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar-C0-6alkyl; R<k> is R<g>, -C(O)R<g>, or -C(O)OR<f>; R<i> is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, Ar-C0-6alkyl, or C1-6alkyl substituted by one to three groups chosen from halogen, CN, NR<g>2, OR<g>, SR<g>, CO2R<g>, and CON(R<g>)2; R<f> is H, C1-6alkyl or Ar-C0-6alkyl; R<e> is H, C1-6alkyl, Ar-C0-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, or (CH2)kCO2R<g>; R<b> and R<c> are independently selected from H, C1-6alkyl, Ar-C0-6alkyl, Het-C0-6alkyl, or C3-6cycloalkyl-C0-6alkyl, halogen, CF3, OR<f>, S(O)kR<f>, COR<f>, NO2, N(R<f>)2, CO(NR<f>)2, CH2N(R<f>)2, or R<b> and R<c> are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, C1-4alkyl, OR<f>, S(O)kR<f>, COR<f>, CO2R<f>, OH, NO2, N(R<f>)2, CO(NR<f>)2, and CH2N(R<f>)2; or methylenedioxy; Q<1>, Q<2>, Q<3> and Q<4> are independently N or C-R<y>, provided that no more than one of Q<1>, Q<2>, Q<3> and Q<4> is N; R' is H, C1-6alkyl, Ar-C0-6alkyl or C3-6cycloalkyl-C0-6alkyl; R" is R', -C(O)R' or -C(O)OR'; R<y> is H, halo, -OR<g>, -SR<g>, -CN, -NR<g>R<k>, -NO2, -CF3, CF3S(O)r-, -CO2R<g>, -COR<g> or -CONR<g>2, or C1-6alkyl optionally substituted by halo, -OR<g>, -SR<g>, -CN, -NR<g>R", -NO2, -CF3, R'S(O)r-, -CO2R<g>, -COR<g> or -CONR<g>2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; u is 0 or 1; and v is 0 or 1; or a pharmaceutically acceptable salt thereof.
|
